Location History:
- Settsu, JP (1986 - 1987)
- Osaka, JP (1985 - 2019)
Company Filing History:
6 out of 257 
3 out of 342 
3 out of 1,393 
Years Active: 1985-2019
Title: Yasuo Yamamoto: Innovator in Melanocortin Receptor Agonists
Introduction
Yasuo Yamamoto is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as melanocortin receptor agonists. With a total of 17 patents to his name, his work has the potential to impact medical treatments significantly.
Latest Patents
Yasuo Yamamoto's latest patents include innovative compounds that demonstrate melanocortin receptor agonistic activity. One of his notable inventions is a substituted imidazole compound, which is described as having a unique structure that allows it to interact effectively with melanocortin receptors. This compound, along with its pharmaceutically acceptable salts, opens new avenues for medical applications. Another significant patent involves a pyrrolidine compound, which also exhibits melanocortin receptor agonist activity. This compound is characterized by its complex structure, which includes various substituents that enhance its pharmaceutical potential.
Career Highlights
Throughout his career, Yasuo Yamamoto has worked with reputable companies in the pharmaceutical industry. He has been associated with Mitsubishi Tanabe Pharma Corporation and Daihen Corporation, where he has contributed to research and development efforts. His expertise in medicinal chemistry and pharmacology has been instrumental in advancing the understanding of melanocortin receptors.
Collaborations
Yasuo Yamamoto has collaborated with notable colleagues in his field, including Katsumi Hanaoka and Masatake Hirai. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical compounds.
Conclusion
Yasuo Yamamoto's contributions to the field of pharmaceuticals, particularly in the area of melanocortin receptor agonists, highlight his role as a leading inventor. His extensive patent portfolio and collaborations with industry professionals underscore his commitment to advancing medical science.